Why did Abbott reduce the merger consideration for Alere?

While the 8-K doesn't explicitly state the reason for the price reduction, the amendment itself and the concurrent settlement agreement suggest that this adjustment was part of resolving disputes and moving towards finalizing the acquisition, potentially addressing issues identified during due diligence or litigation.

What does the extension of the termination date mean for the merger?

The extension of the termination date to September 30, 2017, provides both parties with additional time to satisfy the remaining closing conditions, such as regulatory approvals and Alere shareholder adoption of the amended agreement. It indicates that the merger process is taking longer than initially anticipated.

How does the amendment affect the representations and warranties made by Alere?

The amendment notably carves out matters disclosed in Alere's SEC filings from January 1, 2014, to April 13, 2017, and any information known to Abbott prior to April 13, 2017, from being considered a Material Adverse Effect. It also qualifies Alere's representations and warranties by these disclosures and known matters, potentially limiting Abbott's recourse if issues arise from these specific areas.

What is the impact of the settlement agreement?

The settlement agreement resolves the parties' pending litigation in Delaware Chancery Court. It provides reciprocal releases of claims related to the merger, with specific exceptions. This is a crucial step towards clearing the path for the merger's completion by addressing legal disputes.

ABT 8-K: Material Agreements

Summary

This 8-K filing from Abbott Laboratories (ABT) announces an amendment to the previously agreed-upon merger agreement with Alere Inc. The key change is a reduction in the acquisition price per share for Alere from $56.00 to $51.00 in cash. Additionally, the termination date for the merger agreement has been extended to September 30, 2017, and Alere's potential termination fee payable to Abbott has been reduced. The amendment also includes revised terms regarding how Alere's representations and warranties will be assessed, notably excluding matters disclosed in Alere's public filings since January 1, 2014, and information known to Abbott prior to the amendment date. Furthermore, employee retention commitments for Alere employees joining Abbott have been adjusted. Concurrently, Abbott and Alere entered into a settlement agreement to resolve pending litigation related to the merger, providing reciprocal releases with certain exceptions.

Key Highlights

1Abbott Laboratories (ABT) amended its merger agreement with Alere Inc.
2The acquisition price per share for Alere has been reduced to $51.00 in cash from $56.00.
3The termination date for the merger agreement is extended to September 30, 2017.
4Alere's potential termination fee payable to Abbott has been decreased to $161 million.
5The amendment adjusts the assessment of Alere's representations and warranties, incorporating disclosures and prior knowledge.
6Employee retention commitments for continuing Alere employees have been modified.
7A settlement agreement has been executed to resolve pending litigation between Abbott and Alere concerning the merger.

ABBOTT LABORATORIES 8-K Report, Material Agreement (Apr 14, 2017)

Summary

Key Highlights

Frequently Asked Questions